Successful Treatment of Cryptogenic NORSE Resistant to Immunosuppression With Intravenous Ganaxolone and Electroconvulsive Therapy

Zheng D. Lan, Rishi Malhotra, Ali Naqvi, Megan Barra, Henri Vaitkevicius, Ibrahim Migdady, Division of Critical Care Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Department of Neurology, Albert Einstein College of Medicine, Montefiore Medical Center, Department of Neurological Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, Marinus Pharmaceuticals, Department of Neurosurgery, Division of Neurocritical Care, McGovern School of Medicine, University of Texas Health Science Center

The Neurohospitalist

Published online on November 06, 2025

Abstract

The Neurohospitalist, Volume 16, Issue 2, Page 238-244, April 2026.
Introduction:New Onset Refractory Status Epilepticus (NORSE) occurs without an acute structural, toxic, or metabolic cause in individuals without known epilepsy or a related neurological disease. In about 50% of cases, NORSE is attributed to autoimmune ...